Preliminary results from three Phase 1 clinical trials show that OGX-011 is well tolerated, achieves excellent drug concentrations in prostate
tissue, and produces a 91 percent dose-dependent down-regulation of clusterin in prostate
cancer cells removed from prostate
Arsenic exposure therefore appeared to be associated with the acquisition of androgen independence in prostate
The new results support the use of surgery in some cases of prostate
cancer, comments biostatistician James A.
Grier, 72, has served on the Prostate
Cancer Foundation's board of directors since 1993.
In studies of thousands of men, the risk of prostate
cancer is 70 percent higher in those who consume more alpha-linolenic acid, or ALA--an omega-3 fat found in meat, vegetable oils, and other foods.
The development of the PSA test (prostate
specific antigen) revolutionized prostate
Importantly, patients whose PROSTASCINT fusion image showed their cancer to be limited to the prostate
gland had significantly higher rates of bDFS than those whose image showed uptake outside the prostate
In the present study, we used a model system in which chronic arsenic exposure induced malignant transformation of the human prostate
epithelial cell line RWPE-1 (Achanzar et al.
Second, because not all prostate
cancers release high levels of antigen into the blood, routine PSA screening often fails to detect clinically significant cancers.
The only permanent solution is surgery," Gerber notes, in the most common procedure, called trans-urethral resection of the prostate
(TURP), surgeons "shave" the gland, which helps relieve pressure on the urethra.
Unnecessary treatment for prostate
cancer means more than inflated expenses and needless suffering and anxiety for men and their families.
Mortality rates for prostate
cancer are at an all-time low, the American Cancer Society said, which it attributed to increased use of the PSA - or prostate
specific antigen - blood test to find prostate
cancer early, when it might be more curable.
Cytogen Corporation (NASDAQ: CYTO) today reported the publication of a seven-year survival study that suggests PROSTASCINT([R]) may help predict which patients are less likely to benefit from brachytherapy for prostate
While many men know more about prostate
cancer from firsthand experience than they want to, scientists know less than they would like.
The drug achieves both effects by ratcheting down production of dihydrotestosterone, a hormone linked to male pattern baldness and enlargement of the prostate